about
Non-dietary forms of treatment for adult celiac diseaseInterferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapyTherapeutic approaches for celiac diseaseCurrent and emerging therapy for celiac diseaseSupport for patients with celiac disease: A literature reviewCeliac disease: From pathophysiology to treatment.Small- bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease.Intestinal T-cell responses in celiac disease - impact of celiac disease associated bacteria.Noncontaminated dietary oats may hamper normalization of the intestinal immune status in childhood celiac diseaseThe cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity.Validation of morphometric analyses of small-intestinal biopsy readouts in celiac disease.Reduced-gliadin wheat bread: an alternative to the gluten-free diet for consumers suffering gluten-related pathologies.The effects of reduced gluten barley diet on humoral and cell-mediated systemic immune responses of gluten-sensitive rhesus macaques.Sensory neuronopathy and autoimmune diseasesInterest in medical therapy for celiac disease.Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers.In vitro models for gluten toxicity: relevance for celiac disease pathogenesis and development of novel treatment options.Future treatment strategies for celiac disease.The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Recent advances in the development of new treatments for celiac disease.Advances in the treatment of coeliac disease: an immunopathogenic perspective.Current status of drugs in development for celiac disease.Immunochemical Detection Methods for Gluten in Food Products: Where Do We Go from Here?Coeliac disease - from genetic and immunological studies to clinical applications.Commercially available glutenases: a potential hazard in coeliac disease.Physiopathology and Management of Gluten-Induced Celiac Disease.Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.Identification of food-grade subtilisins as gluten-degrading enzymes to treat celiac disease.Oral enzyme therapy for celiac sprue.Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.Immunopathology of childhood celiac disease-Key role of intestinal epithelial cellsCYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease.Celiac disease: a challenging disease for pharmaceutical scientists.Scientific Opinion on the evaluation of allergenic foods and food ingredients for labelling purposesAdministration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease.Are Transglutaminase 2 Inhibitors Able to Reduce Gliadin-Induced Toxicity Related to Celiac Disease? A Proof-of-Concept Study
P2860
Q24602271-68EA51FD-D536-41C7-A1BF-7FA4420ACCBDQ24611233-8C920619-164D-44C3-B529-1D7EC56E3230Q26825413-924C683A-43B6-4CFB-AFBD-BEF80FBA52C2Q27014843-D0B5AA52-39D3-41BE-B5A6-8DF29D62E906Q27026918-07D194DA-2E7F-45DC-91EB-290FE7310107Q30234291-4AFC12A0-FC8B-4DB0-B47B-F9CD39AF864CQ34083093-4B42CA83-1F2D-45C5-BD12-AFB040C607E0Q34551370-1314B151-74B7-4303-8F66-FBC1CB277D98Q34662703-513E0F52-DC94-4E59-87DC-7BF3E1EBDA4FQ34743085-6A30E8A7-4C91-4CB0-82B3-FE7332594220Q35022655-45CB85D2-B318-447C-902B-8AE95C9A277DQ35118668-84EC8072-4DCD-477B-B2BE-2B2FE8BBBBADQ35227859-F7E85E1D-4775-41C0-AFA0-4EA081B74A81Q35726020-974F08AD-83E0-4068-ADBB-E686DADA514CQ37130612-5633CD07-8309-4C0F-97F9-7B55B2B3A6F2Q37275552-5E6056D4-B095-43EF-B14A-AE5A16A729D9Q37979161-630083A3-0D00-493D-B2DE-BC2F35776315Q38012460-6B6E246F-2DED-4EDB-8F6E-20D8DB51E91FQ38016781-12467DF6-83FC-4D68-8DCA-AD935DF59286Q38038684-B95E6928-C9BF-4CDC-8D60-273829BDF54EQ38126789-524AE809-47FF-4C14-9701-949658E710BDQ38210088-84E6433A-52E4-473F-BC4D-152C7DEE6157Q38380946-659CABC3-15FA-4909-A302-292C5AD97FB9Q38408084-A0208085-50F1-4E53-938E-D8B413482E85Q38752372-0B1FA41C-3E84-4C5B-8F15-910064B65377Q39111493-86BAE534-AF3A-47E9-8FFA-DFCC9CE90853Q41348755-EC7F53B1-C2A9-4CA1-A79B-0FEC383CD661Q41546021-78D72D3A-8A04-4AB6-ADC9-E3E7FA58B5B9Q42212923-4FEF0934-D6AC-4BD8-9FEB-419DA5993210Q42272148-89FF8000-33C2-4288-8380-5A580D612B03Q42362099-F1EED54B-70A8-49D4-B27D-3313E7BFFC60Q43665284-7E397643-3EEC-4317-9E32-BE68AFC3A9C8Q45254873-83DEAD75-94BF-4AF1-8CAB-AEE21A338D2FQ47155140-D14B2C2F-0845-4D6A-B1B1-E2D8A9D417C6Q53444099-3067D03C-22BD-43C8-BFA3-48992A5EF11FQ57937529-DFC7CAAC-E156-4226-90A6-A9EFC7CDAD73
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Novel therapies for coeliac disease
@ast
Novel therapies for coeliac disease
@en
Novel therapies for coeliac disease
@nl
type
label
Novel therapies for coeliac disease
@ast
Novel therapies for coeliac disease
@en
Novel therapies for coeliac disease
@nl
prefLabel
Novel therapies for coeliac disease
@ast
Novel therapies for coeliac disease
@en
Novel therapies for coeliac disease
@nl
P2860
P1476
Novel therapies for coeliac disease
@en
P2093
P2860
P304
P356
10.1111/J.1365-2796.2011.02376.X
P407
P577
2011-06-01T00:00:00Z